To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (Progress)

  • End date
    Dec 2, 2024
  • participants needed
  • sponsor
    Incyte Corporation
Updated on 16 September 2023


This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).

Condition Fibrodysplasia Ossificans Progressiva (FOP)
Treatment Placebo, INCB000928
Clinical Study IdentifierNCT05090891
SponsorIncyte Corporation
Last Modified on16 September 2023


Yes No Not Sure

Inclusion Criteria

Female and male adults and adolescents ≥ 12 years of age with a diagnosis of FOP
Willingness to avoid pregnancy or fathering children based on the criteria below
Willing and able to undergo low-dose WBCT (excluding the head) imaging without requiring intubation
Further inclusion criteria apply

Exclusion Criteria

Pregnant or breast-feeding
CAJIS score ≥ 24
FOP disease severity that in the investigator's opinion precludes participation
Any clinically significant medical condition other than FOP that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the participant, or interfere with interpretation of study data
Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
HIV, HBV, or HCV infection. Note
Further exclusion criteria apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note